NERV Stock Analysis: Buy, Sell, or Hold?
NERV - Minerva Neurosciences, Inc
$5.28
-0.32 (-5.71%)
▼
5d:
-14.01%
30d:
-22.69%
90d:
+31.34%
WAIT
LOW Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 12, 2026
Get Alerted When NERV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NERV is down 14.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NERV is down 14.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NERV is currently trading at $5.28, which is considered oversold relative to its 30-day fair value range of $5.93 to $7.58.
Technical Outlook: Technically, NERV is showing support break momentum. The price is currently testing key support at $5.40. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. However, the stock is trading significantly above the average Wall Street target of $4.00. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NERV is showing support break momentum. The price is currently testing key support at $5.40. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. However, the stock is trading significantly above the average Wall Street target of $4.00. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$5.93 -
$7.58
Company Quality Score
40/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.7%)
- BEARISH: Trading 24.2% above Wall St target ($4.00)
- WARNING: Recommendation downgraded due to -14.0% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$5.93 -
$7.58
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$5.40
Resistance Level
$8.17
Current Trend
Support Break
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.78
Wall Street Target
$4.00
(-24.2%)
Share & Embed Analysis
Last updated: April 02, 2026 9:57 PM ET
Data refreshes hourly during market hours. Next update: 10:57 PM
Data refreshes hourly during market hours. Next update: 10:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NERV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 58 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$873 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 46 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 61 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$224 | 60 HOLD |
